Kamada (KMDA) Total Liabilities (2012 - 2026)
Kamada's (KMDA) quarterly Total Liabilities came in at $113.6 million in Q2 2026, up 4.98% on a YoY basis from $108.2 million in Q2 2025, and down 8.11% quarter-over-quarter from $123.6 million in Q1 2026.
Analysis
Kamada (KMDA) Total Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Total Liabilities for 15 consecutive years, with $113.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities rose 4.98% year-over-year to $113.6 million; the trailing twelve-month figure through Jun 2026 stood at $113.6 million (up 4.98% YoY), and the FY2025 full-year result was $37.2 million, up 813.49% from the prior year.
- Total Liabilities retreated to $113.6 million in Q2 2026 per KMDA's latest filing, from $123.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $304.0 million in Q2 2022 and bottomed at $4.1 million in Q4 2024.
- Historically, Total Liabilities has averaged $112.1 million across 5 years, with a median of $112.8 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 61385.83% in 2022, then plunged 96.98% in 2023.
- Over 5 years, Total Liabilities stood at $146.4 million in 2022, then slumped by 96.98% to $4.4 million in 2023, then retreated by 7.92% to $4.1 million in 2024, then surged by 813.49% to $37.2 million in 2025, then soared by 205.63% to $113.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $113.6 million, $123.6 million, and $37.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 113.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 113.60 Mn |
| Mar 31, 2026 | 123.63 Mn |
| Dec 31, 2025 | 37.17 Mn |
| Sep 30, 2025 | 111.98 Mn |
| Jun 30, 2025 | 108.22 Mn |
| Mar 31, 2025 | 123.15 Mn |
| Dec 31, 2024 | 4.07 Mn |
| Sep 30, 2024 | 95.94 Mn |
| Jun 30, 2024 | 99.89 Mn |
| Mar 31, 2024 | 92.02 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Sep 30, 2023 | 98.67 Mn |
| Jun 30, 2023 | 137.64 Mn |
| Mar 31, 2023 | 141.99 Mn |
| Dec 31, 2022 | 146.36 Mn |
| Sep 30, 2022 | 147.09 Mn |
| Jun 30, 2022 | 303.96 Mn |
| Mar 31, 2022 | 127.95 Mn |
| Dec 31, 2021 | 141.84 Mn |
| Sep 30, 2021 | -240,000.00 |